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Drug-resistance mechanisms and tuberculosis drugs
Bedaquiline and delamanid, novel classes of anti-
tuberculosis drugs, have been recently approved for 
the treatment of multidrug-resistant tuberculosis.1 
Antimicrobial resistance invariably follows the 
introduction of new drugs, and appropriate drug-
susceptibility testing assays are needed to detect 
resistance and tailor treatment regimens that contain 
new agents.2,3 Given that phenotypic drug-susceptibility 
testing is slow, technically demanding, and, in some 
cases, unreliable, future assays are likely to be based 
on rapid molecular techniques. To design such assays, 
research to unravel the genetic basis of resistance is 
urgently required (appendix).2 The question is how to 
ensure that this research occurs in a timely way, before 
the emergence and spread of resistance.
A potential solution is to link the elucidation of 
resistance mechanisms to the approval process for 
new antibiotics, as is already the case for resistance to 
antivirals.4–6 Where appropriate, this approach should also 
include the resistance mechanisms of older antibiotics 
that will be included in new regimens. For many bacteria 
and antibiotics it is not feasible to identify resistance 
before market release because of horizontal transfer of 
resistance genes between bacteria. By contrast, resistance 
in the Mycobacterium tuberculosis complex (MTBC) 
arises exclusively by chromosomal changes.7 Therefore, 
mechanisms of resistance can be studied by multiple 
methods, including the selection of drug-resistant 
mutants in vitro and in-vivo animal infection models, and 
by examining drug-resistant mutants from clinical trials.8
Next-generation sequencing showed that 
bedaquiline resistance arises through mutations in 
the ATP synthase.9,10 Yet it was only after regulatory 
approval of bedaquiline—and more than 8 years after 
the identiﬁ cation of the target of bedaquiline—that 
it was shown that resistance can also arise through 
the mutational upregulation of an eﬄ  ux pump.8,10,11 
Importantly, this mechanism also confers cross-
resistance to clofazimine.3,8,11 As a result, regimens that 
contain both drugs might have to be reconsidered 
if these mutations are found to be common and to 
increase the minimum inhibitory concentrations 
signiﬁ cantly to reduce treatment success.12,13 It is 
questionable whether these regimens would have 
been evaluated at all, had the bedaquiline resistance 
mechanisms been elucidated comprehensively in 
the early stages of drug development. Moreover, had 
this genetic information been available at the time of 
approval of bedaquiline, regulators might have required 
for this cross-resistance to be formally labelled.3,8,11
The early identiﬁ cation of resistance mechanisms 
would also minimise the chance of developing 
antibiotics that are not eﬀ ective across the world.7 
Clinical trials only include patients infected with a 
limited number of MTBC genotypes, which raises the 
possibility that intrinsic antibiotic resistance could 
be missed.7 By contrast, intrinsically resistant strains 
could be screened for by assessing the conservation of 
resistance genes in the genomes of the thousands of 
phylogenetically diverse MTBC isolates that have been 
sequenced to date.7 This approach has already raised 
the possibility that Mycobacterium canettii, which causes 
tuberculosis in the Horn of Africa and is intrinsically 
resistant to pyrazinamide, might also be intrinsically 
resistant to PA-824.7,14 Consequently, the regimen of 
PA-824/pyrazinamide/moxiﬂ oxacin, which is about 
to be assessed in phase 3 clinical trials, might lead to 
monotherapy of patients with M canettii infection.12
The development and periodic revision of guidelines 
to determine resistance mechanisms as part of drug 
development would beneﬁ t from close cooperation 
between academic experts, funding agencies, 
pharmaceutical companies, and regulatory authorities, 
as has occurred for antivirals in the past.3-6,15 Such work 
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would require a ﬂ exible approach, depending on the 
properties of the particular antibiotic. For example, 
it might not be readily possible to select for in-vitro 
resistance to some agents.16 An analysis of the detailed 
mechanism of resistance would be desirable but not 
essential for the approval of new agents.
There would be many advantages in sharing the 
resulting strain collections, sequence data, markers of 
resistance, and drug-susceptibility testing results, as is 
standard practice in HIV research.17 We, therefore, have 
serious concerns about the patenting of resistance 
mechanisms, which has already occurred for several 
tuberculosis resistance mechanisms. For example, a 
university patented the “isolated” nucleic acid sequence 
of pncA (patent number US5846718), mutations in 
which confer resistance to pyrazinamide. This claim  was 
probably invalidated by the US Supreme Court ruling in 
Association for Molecular Pathology v. Myriad Genetics 
in 2013, which found that a “naturally occurring DNA 
segment is a product of nature and not patent-eligible 
merely because it has been isolated”.18 This ruling has no 
direct bearing on the equivalent pncA patents granted in 
Canada (CA2254828) and Europe (EP0904410), all of 
which have lapsed for other reasons.
The patenting of isolated genes remains legal in many 
countries, as aﬃ  rmed most recently by the Federal Court 
of Australia.19,20 More recently, the same university ﬁ led 
a patent for the detection of rpsA mutations as a marker 
for pyrazinamide resistance that could potentially cover 
any molecular method to detect mutations in this 
gene.21 In light of the ruling by the US Supreme Court in 
Mayo v. Prometheus, however, a biomarker patent of 
this kind is unlikely to be valid in the USA because the 
correlation between rpsA mutations and pyrazinamide 
resistance would be regarded as a law of nature.18 
Whether similar biomarker patents could be refused or 
invalidated in other jurisdictions is less clear. 
Irrespective of the legality of such patents, we are 
concerned by attempts to monopolise knowledge about 
resistance mechanisms, including through the use of 
trade secrets in relation to clinical data.22 Understanding 
resistance mechanisms is vital for the safe and eﬀ ective 
treatment of patients, as well as for long-term antibiotic 
stewardship. The early and comprehensive elucidation 
of resistance mechanisms to drugs for tuberculosis 
during drug development is in the common interest 
of patients, clinicians, academics, and pharmaceutical 
companies. Moreover, the resulting knowledge 
should be made publicly available at no cost. This 
needs appropriate regulatory and business models for 
antibiotic drug development that promote or mandate 
public sharing of knowledge about resistance and its 
mechanisms,17 as well as addressing the many other 
tensions in antibiotic innovation.23
*Claudio U Köser, Babak Javid, Kathleen Liddell, 
Matthew J Ellington, Silke Feuerriegel, Stefan Niemann, 
Nicholas M Brown, William J Burman, Ibrahim Abubakar, 
Nazir A Ismail, David Moore, Sharon J Peacock, M Estée Török
Department of Medicine, Addenbrooke’s Hospital, University of 
Cambridge, Cambridge CB2 0QW, UK (CUK, BJ, SJP, MET); School 
of Medicine, Tsinghua University, Beijing, China (BJ); Faculty of 
Law, University of Cambridge, Cambridge, UK (KL); Clinical 
Microbiology and Public Health Laboratory, Public Health England, 
Cambridge, UK (MJE, NMB, SJP, MET); Molecular 
Mycobacteriology, Research Center Borstel, Borstel, Germany (SF, 
SN); German Centre for Infection Research, Borstel, Germany (SF); 
Denver Public Health, Denver, USA (WJB); Tuberculosis Section, 
Centre for Infectious Disease Surveillance and Control, Public 
Health England, London, UK (IA); Research Department of 
Infection and Population Health, University College London, 
London, UK (IA); Centre for Tuberculosis, National Institute for 
Communicable Diseases, Johannesburg, South Africa (NAI); TB 
Centre, London School of Hygiene and Tropical Medicine, London, 
UK (DM); Laboratorio de Investigación de Enfermedades 
Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru 
(DM); Cambridge University Hospitals NHS Foundation Trust, 
Cambridge, UK (SJP, MET); and Wellcome Trust Sanger Institute, 
Wellcome Trust Genome Campus, Hinxton, UK (SJP)
cuk21@cam.ac.uk
This publication presents independent research supported by the Health Innovation 
Challenge Fund (HICF-T5-342 and WT098600), a parallel funding partnership 
between the UK Department of Health and Wellcome Trust. The views expressed in 
this publication are those of the authors and not necessarily those of the Department 
of Health, Public Health England, or the Wellcome Trust. CUK received travel 
expenses to a scientiﬁ c meeting from Janssen. CUK, SN, and SJP are collaborating 
with the TB Alliance and Otsuka Pharmaceutical to test the in-vitro potency of 
delamanid, PA-824, and TBA-354. BJ is a Tsinghua-Janssen Scholar. MJE was funded 
by Bruker Daltonics to attend a conference. NMB is a consultant for Discuva Ltd, was 
funded by Astellas Pharma Ltd to attend a conference, and is the President of the 
British Society for Antimicrobial Chemotherapy. WJB chairs the Data and Safety 
Monitoring Boards for clinical trials of bedaquiline. SJP has received funding for travel 
and accommodation from Illumina Inc. MET was funded by Illumina Inc to attend a 
conference. KL, IA, NAI, and KL declare no competing interests. 
1 Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, 
regimens, and adjunct therapies: needs, advances, and future prospects. 
Lancet Infect Dis 2014; 14: 327–40. 
2 Wells WA, Boehme CC, Cobelens FG, et al. Alignment of new tuberculosis 
drug regimens and drug susceptibility testing: a framework for action. 
Lancet Infect Dis 2013; 13: 449–58.
3 Somoskovi A, Bruderer V, Hömke R, Bloemberg GV, Böttger EC. A mutation 
associated with clofazimine and bedaquiline cross-resistance in MDR-TB 
following bedaquiline treatment. Eur Respir J 2014; published online Oct 30. 
DOI:10.1183/09031936.00142914.
4 Shafer RW, Schapiro JM. Drug resistance and antiretroviral drug 
development. J Antimicrob Chemother 2005; 55: 817–20.
Comment
www.thelancet.com   Vol 385   January 24, 2015 307
Familial hypercholesterolaemia is an inherited 
disorder that substantially increases risk of coronary 
artery disease.1,2 Recent population data show that 
the heterozygous and homozygous forms of familial 
hypercholesterolaemia aﬀ ect one in 2001 and one in 
160 000–300 000 people,3 respectively, worldwide. 
Plasma concentrations of LDL cholesterol (LDL-C) are 
increased in the disorder because of hypocatabolism of 
LDL particles by the liver, which is related to the severity 
of underlying genetic mutations mostly aﬀ ecting the 
LDL receptor gene. The clinical sequelae are tendon 
xanthomas, premature coronary artery disease, and, in 
homozygous familial hypercholesterolaemia, valvular or 
supravalvular aortic stenosis.4 The raised risk of coronary 
artery disease in familial hypercholesterolaemia is caused 
by lifelong exposure to high LDL-C from birth.1 Recent 
evidence has also reaﬃ  rmed a proatherogenic eﬀ ect 
of raised concentrations of the LDL-like particle plasma 
lipoprotein(a).5
Statins lower plasma LDL-C concentrations and 
improve coronary artery disease outcomes and survival 
in familial hypercholesterolaemia6 by increasing 
hepatic expression of the LDL receptor and plasma 
clearance of LDL. Proprotein convertase subtilisin/
kexin type 9 (PCSK9) is a secretory serine protease that 
homoeostatically regulates the amount of plasma LDL-C 
by interacting with the LDL receptor.7 After binding 
and internalisation, PCSK9 directs the LDL receptor to 
lysosomal degradation, inhibiting its recycling to the 
hepatocyte surface and thus catabolism of plasma LDL. 
Therapeutic inhibition of HMGCoA reductase by statins 
upregulates PCSK9,7 limiting the eﬀ ectiveness of statins 
in lowering plasma LDL-C. Gain-of-function mutations 
in the PCSK9 gene cause a phenotype that mimics 
familial hypercholesterolaemia.1,7
Despite the eﬀ ectiveness of cholesterol-
lowering therapies, most patients with familial 
hypercholesterolaemia cannot achieve plasma 
LDL cholesterol targets recommended to prevent 
cardiovascular events.1,8 This challenge is virtually 
universal in patients with homozygous familial 
hypercholesterolaemia, for whom an apoB100 antisense 
oligonucleotide (mipomersen)9 and a microsomal 
triglyceride transfer protein inhibitor (lomitapide)10 
were recently approved as adjunctive treatments that 
can reduce LDL-C by a further 25–40%.9,10 However, 
this reduction is achieved at substantially increased 
monetary costs and clinical side-eﬀ ects.9–11
The recent development of monoclonal antibodies 
against PCSK9 is a revolution in the treatment of 
familial and other types of hypercholesterolaemia. These 
drugs, injected subcutaneously every 15 or 30 days, bind 
Familial hypercholesterolaemia: PCSK9 inhibitors are coming
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